# Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

> **NCT00130000** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 87 (—)

## Conditions studied

- Paroxysmal Hemoglobinuria, Nocturnal

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT00130000
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08-09
- **Primary completion:** —
- **Final completion:** 2007-06-25
- **Target enrollment:** 87 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130000, "Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00130000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*